Ch
Chiesi
Parma ITFounded 19356,000 employees
Private CappharmaPrivateRespiratoryRare Disease
Platform: Rare Resp
Market Cap
N/A
All Drugs
4
Clinical Trials
9
Failed / Terminated
1
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Miriosocimab | CHI-7935 | Phase 3 | 1 | MALT1 | MG | ||
| CHI-2221 | CHI-2221 | Phase 3 | 4 | SOS1 | AML | ||
| Ivotinib | CHI-1514 | Phase 3 | 2 | BTK | CTCL | ||
| Gelitenlimab | CHI-8804 | Phase 1/2 | 2 | BTK | ACCPsA |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (7)